Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) originated as BCTG Acquisition Corp, a blank-check company sponsored by BCTG Sponsor LLC, an entity affiliated with Boxer Capital and Cormorant Asset Management, which completed its initial public offering on Nasdaq in 2020. The SPAC operated in the healthcare and biotechnology sector and completed its business combination with Tango Therapeutics — a clinical-stage precision oncology company focused on synthetic lethality — in October 2021. The June 2024 8-K represents a post-combination corporate disclosure by the surviving public entity, which has continued advancing its pipeline of targeted cancer therapies. For comprehensive SPAC deal histories, sponsor profiles, and real-time filing alerts on Tango Therapeutics and hundreds of other transactions, sign up for full access at SpacDesk.